Shooting Cancer

2 03, 2023

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – January 2023

adlitterio663392023-03-02T10:16:43+01:00

Read More

11 01, 2023

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – November and December 2022

adlitterio663392023-01-11T12:13:39+01:00

Read More

10 10, 2022

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – September 2022

adlitterio663392022-10-11T16:23:17+02:00

Read More

8 09, 2022

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – August 2022

adlitterio663392022-09-08T14:15:04+02:00

Read More

4 08, 2022

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – July 2022

adlitterio663392022-08-04T09:42:52+02:00

Read More

18 07, 2022

Monthly focus on regulatory status of new targeted therapies in oncology – June 2022

adlitterio663392022-07-18T11:28:45+02:00

Read More

27 06, 2022

Monthly focus on regulatory status of new targeted therapies in oncology – May 2022

adlitterio663392022-06-27T12:11:23+02:00

Read More

20 05, 2022

Monthly focus on regulatory status of new targeted therapies in oncology – April 2022

Diatech Pharmacogenetics2022-05-20T11:08:27+02:00

Read More

12 04, 2022

Monthly focus on regulatory status of new targeted therapies in oncology- March 2022

Diatech Pharmacogenetics2022-04-12T17:29:57+02:00

Read More

12 04, 2022

ALK rearrangements: a biomarker at the forefront of NSCLC treatment

Diatech Pharmacogenetics2022-04-12T12:17:10+02:00

Read More